These beneficial effects, in addition to metabolic improvements in glycemic control and weight reduction, provide a compelling rationale for the further study of GLP-1 RAs in non-diabetic kidney diseases like AS. The gene discussed is GLP1R; the disease is diabetic kidney disease.